{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":26,"n_cols":5,"rows_kept":26,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[11,2,11,3],[15,2,15,3],[16,2,16,3],[20,2,20,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910145440203321"]
[null,null,"Titolo",null,"Immune dysfunction and immunotherapy in heart disease [[electronic resource] /] / edited by Ronald Ross Watson & Douglas F. Larson"]
[null,null,"Pubbl/distr/stampa",null,"Oxford, : Blackwell, 2007"]
[null,null,"ISBN",null,"1-281-06941-8"]
[{"$nulls":4},"9786611069414"]
[{"$nulls":4},"0-470-69232-4"]
[{"$nulls":4},"0-470-76651-4"]
[null,null,"Descrizione fisica",null,"1 online resource (323 p.)"]
[null,null,"Classificazione",null,"YB 9022"]
[null,null,"Disciplina",null,"616.1/207"]
[{"$nulls":4},"616.1207"]
[null,null,"Soggetti",null,"Heart - Diseases - Immunological aspects"]
[{"$nulls":4},"Heart - Diseases - Immunotherapy"]
[{"$nulls":4},"Immunologic diseases - Complications"]
[{"$nulls":4},"Electronic books."]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Immune Dysfunction and Immunotherapy in Heart Disease; Contents; Contributors; Preface; About the Editors; Part I Immune dysfunction leading to heart disease: induction by physiological changes; 1 Immunosuppression by ultraviolet light-B radiation: a mediator of cardiac remodeling; 2 Immune mechanisms in pediatric cardiovascular disease; 3 Heart failure-role of autoimmunity; 4 Immune basis of hypertension in humans; 5 Immune dysregulation: potential mediator metabolic syndrome-induced cardiac remodeling; 6 T helper 2 cell cytokines in remodeling of aortic wall"]
[{"$nulls":4},"7 Effects of TNF-a on cardiac function8 Immunosuppression in promotion of cardiac allograft vasculopathy; 9 Immunotherapy for left ventricular dysfunction after heart transplantation; Part II Immune dysfunction promoting CVD: induction by transplantation drugs; 10 Immunomodulating therapy in chronic heart failure; 11 Statins in atherosclerosis: role of immune regulation; 12 ACE inhibitors as immunomodulators: treatment of cardiovascular disease; 13 Treatment of heart failure by anticytokine therapies"]
[{"$nulls":4},"Part III Immune dysfunction leading to heart dysfunction: induction or prevention by cardiotherapeutic drugs14 Pathogenesis of "]
[{"$nulls":4},"cardiovascular complications in the acquired immunodeficiency syndrome; 15 Cytokines and T cell-mediated responses in autoimmune myocarditis; 16 Drugs of abuse: accentuation of immunomodulation of viral myocarditis; Part IV Immune dysfunction leading to heart disease: induction by pathogens; 17 Osteopontin: the link between the immune system and cardiac remodeling; 18 Inflammatory immune activation in heart failure patients: therapeutic implications"]
[{"$nulls":4},"26 Role of oral pathogens in the pathogenesis of coronary heart disease27 Myocardial regenerative potential by stem cell transplant; 28 Bioflavanoids and dietary anti-inflammatory actions: role in cardiovascular diseases; Index"]
[null,null,null,"Sommario/riassunto","Current heart failure therapeutics affects symptoms without appreciably reducing the mortality rate of 50% in five years -- suggesting a failure in treating the underlying mechanism. This book proposes a new mechanism for heart failure; immune mediated cardiac remodelling for cardiac dysfunction. The outstanding editor team of two internationally recognized immunologists -- Ronald Watson, who has studied heart disease in immune dysfunction for a decade and has a patent for an immunotherapy of heart disease by immune regulation, and Douglas Larson, whose experience in cardiac transplantat"]